English
简体中文
Total: £ 56.28
Published Date: 2025-12-17 | Pages: 106 | Tables: 101 | Pharma & Healthcare
The global market for Intravitreal Injections was valued at US$ 17965 million in the year 2024 and is projected to reach a revised size of US$ 28698 million by 2031, growing at a CAGR of 7.1% during the forecast period.
Intravitreal injections refer to pharmaceutical agents administered directly into the vitreous cavity of the eye, enabling high intraocular bioavailability for treating retinal diseases such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic CNV. These agents include anti-VEGF biologics, corticosteroid implants, sustained-release injectables, and emerging gene-therapy vectors. As retinal diseases continue rising globally due to aging populations, diabetes prevalence, and increased myopia, intravitreal injections remain the gold-standard treatment modality in ophthalmology.
The upstream segment consists of biologics manufacturing platforms, recombinant protein expression systems, viral vector producers, and excipient suppliers specializing in sterile injectables. High-purity raw materials, aseptic fill-finish capabilities, and cold-chain logistics are essential due to the biological and temperature-sensitive nature of these drugs. Midstream players are the pharmaceutical companies responsible for drug formulation, clinical development, regulatory approval, large-scale GMP production, and packaging in prefilled syringes or sterile vials.
Downstream, ophthalmologists, retina specialists, hospitals, and ambulatory surgical centers deliver the injections to patients, while distributors and specialty pharmacies manage storage, reimbursement, and last-mile delivery. Health-insurance systems—including Medicare/Medicaid in the U.S. and national health insurers in Europe—play a central role in determining pricing, uptake, and treatment frequency, making reimbursement a crucial commercial success factor.
Gross margins in the intravitreal injection market are among the highest in specialty pharmaceuticals, typically ranging from 65% to 85% for leading biologics such as anti-VEGF agents. High barriers to entry, strong patent protection, complex manufacturing, and the clinical necessity of repeated dosing support elevated profitability. Steroid implants and sustained-release technologies exhibit slightly lower but still attractive margins due to device-drug combination complexity.
This report aims to provide a comprehensive presentation of the global market for Intravitreal Injections, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intravitreal Injections.
The Intravitreal Injections market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Intravitreal Injections market comprehensively. Regional market sizes, concerning products by Drug, by Disease, by Formulation Type and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Intravitreal Injections companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Drug, by Disease, and by regions.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Bausch & Lomb
Novartis
AbbVie (Allergan)
Alimera Sciences
Roche
Bristol-Myers Squibb
Bayer
Bausch + Lomb
EyePoint Pharmaceuticals
Segment by Drug
Anti-VEGF Agents
Corticosteroids / Steroid Implants
Thrombolytic / Enzymatic Agents
Others
Segment by Formulation Type
Solution for Intravitreal Injection
Suspension for Intravitreal Injection
Others
Segment by Duration of Action
Short-acting (4–6 weeks)
Medium-acting (8–12 weeks)
Long-acting (> 6 months)
Segment by Disease
Macular Degeneration
Macular Edema
Uveitis
Retinal Vein Occlusion
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Drug, by Disease, by Formulation Type etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Intravitreal Injections company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Drug, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Disease, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Drug
1.2.1 Global Intravitreal Injections Market Size Growth Rate by Drug: 2020 VS 2024 VS 2031
1.2.2 Anti-VEGF Agents
1.2.3 Corticosteroids / Steroid Implants
1.2.4 Thrombolytic / Enzymatic Agents
1.2.5 Others
1.3 Market by Formulation Type
1.3.1 Global Intravitreal Injections Market Size Growth Rate by Formulation Type: 2020 VS 2024 VS 2031
1.3.2 Solution for Intravitreal Injection
1.3.3 Suspension for Intravitreal Injection
1.3.4 Others
1.4 Market by Duration of Action
1.4.1 Global Intravitreal Injections Market Size Growth Rate by Duration of Action: 2020 VS 2024 VS 2031
1.4.2 Short-acting (4–6 weeks)
1.4.3 Medium-acting (8–12 weeks)
1.4.4 Long-acting (> 6 months)
1.5 Market by Disease
1.5.1 Global Intravitreal Injections Market Growth by Disease: 2020 VS 2024 VS 2031
1.5.2 Macular Degeneration
1.5.3 Macular Edema
1.5.4 Uveitis
1.5.5 Retinal Vein Occlusion
1.5.6 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Intravitreal Injections Market Perspective (2020-2031)
2.2 Global Intravitreal Injections Growth Trends by Region
2.2.1 Global Intravitreal Injections Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Intravitreal Injections Historic Market Size by Region (2020-2025)
2.2.3 Intravitreal Injections Forecasted Market Size by Region (2026-2031)
2.3 Intravitreal Injections Market Dynamics
2.3.1 Intravitreal Injections Industry Trends
2.3.2 Intravitreal Injections Market Drivers
2.3.3 Intravitreal Injections Market Challenges
2.3.4 Intravitreal Injections Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Intravitreal Injections Players by Revenue
3.1.1 Global Top Intravitreal Injections Players by Revenue (2020-2025)
3.1.2 Global Intravitreal Injections Revenue Market Share by Players (2020-2025)
3.2 Global Top Intravitreal Injections Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Intravitreal Injections Revenue
3.4 Global Intravitreal Injections Market Concentration Ratio
3.4.1 Global Intravitreal Injections Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Intravitreal Injections Revenue in 2024
3.5 Global Key Players of Intravitreal Injections Head office and Area Served
3.6 Global Key Players of Intravitreal Injections, Product and Application
3.7 Global Key Players of Intravitreal Injections, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Intravitreal Injections Breakdown Data by Drug
4.1 Global Intravitreal Injections Historic Market Size by Drug (2020-2025)
4.2 Global Intravitreal Injections Forecasted Market Size by Drug (2026-2031)
5 Intravitreal Injections Breakdown Data by Disease
5.1 Global Intravitreal Injections Historic Market Size by Disease (2020-2025)
5.2 Global Intravitreal Injections Forecasted Market Size by Disease (2026-2031)
6 North America
6.1 North America Intravitreal Injections Market Size (2020-2031)
6.2 North America Intravitreal Injections Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Intravitreal Injections Market Size by Country (2020-2025)
6.4 North America Intravitreal Injections Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Intravitreal Injections Market Size (2020-2031)
7.2 Europe Intravitreal Injections Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Intravitreal Injections Market Size by Country (2020-2025)
7.4 Europe Intravitreal Injections Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Intravitreal Injections Market Size (2020-2031)
8.2 Asia-Pacific Intravitreal Injections Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Intravitreal Injections Market Size by Region (2020-2025)
8.4 Asia-Pacific Intravitreal Injections Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Intravitreal Injections Market Size (2020-2031)
9.2 Latin America Intravitreal Injections Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Intravitreal Injections Market Size by Country (2020-2025)
9.4 Latin America Intravitreal Injections Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Intravitreal Injections Market Size (2020-2031)
10.2 Middle East & Africa Intravitreal Injections Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Intravitreal Injections Market Size by Country (2020-2025)
10.4 Middle East & Africa Intravitreal Injections Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Company Details
11.1.2 Regeneron Pharmaceuticals Business Overview
11.1.3 Regeneron Pharmaceuticals Intravitreal Injections Introduction
11.1.4 Regeneron Pharmaceuticals Revenue in Intravitreal Injections Business (2020-2025)
11.1.5 Regeneron Pharmaceuticals Recent Development
11.2 Bausch & Lomb
11.2.1 Bausch & Lomb Company Details
11.2.2 Bausch & Lomb Business Overview
11.2.3 Bausch & Lomb Intravitreal Injections Introduction
11.2.4 Bausch & Lomb Revenue in Intravitreal Injections Business (2020-2025)
11.2.5 Bausch & Lomb Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Intravitreal Injections Introduction
11.3.4 Novartis Revenue in Intravitreal Injections Business (2020-2025)
11.3.5 Novartis Recent Development
11.4 AbbVie (Allergan)
11.4.1 AbbVie (Allergan) Company Details
11.4.2 AbbVie (Allergan) Business Overview
11.4.3 AbbVie (Allergan) Intravitreal Injections Introduction
11.4.4 AbbVie (Allergan) Revenue in Intravitreal Injections Business (2020-2025)
11.4.5 AbbVie (Allergan) Recent Development
11.5 Alimera Sciences
11.5.1 Alimera Sciences Company Details
11.5.2 Alimera Sciences Business Overview
11.5.3 Alimera Sciences Intravitreal Injections Introduction
11.5.4 Alimera Sciences Revenue in Intravitreal Injections Business (2020-2025)
11.5.5 Alimera Sciences Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Intravitreal Injections Introduction
11.6.4 Roche Revenue in Intravitreal Injections Business (2020-2025)
11.6.5 Roche Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Details
11.7.2 Bristol-Myers Squibb Business Overview
11.7.3 Bristol-Myers Squibb Intravitreal Injections Introduction
11.7.4 Bristol-Myers Squibb Revenue in Intravitreal Injections Business (2020-2025)
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Bayer
11.8.1 Bayer Company Details
11.8.2 Bayer Business Overview
11.8.3 Bayer Intravitreal Injections Introduction
11.8.4 Bayer Revenue in Intravitreal Injections Business (2020-2025)
11.8.5 Bayer Recent Development
11.9 Bausch + Lomb
11.9.1 Bausch + Lomb Company Details
11.9.2 Bausch + Lomb Business Overview
11.9.3 Bausch + Lomb Intravitreal Injections Introduction
11.9.4 Bausch + Lomb Revenue in Intravitreal Injections Business (2020-2025)
11.9.5 Bausch + Lomb Recent Development
11.10 EyePoint Pharmaceuticals
11.10.1 EyePoint Pharmaceuticals Company Details
11.10.2 EyePoint Pharmaceuticals Business Overview
11.10.3 EyePoint Pharmaceuticals Intravitreal Injections Introduction
11.10.4 EyePoint Pharmaceuticals Revenue in Intravitreal Injections Business (2020-2025)
11.10.5 EyePoint Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Intravitreal Injections Market Size Growth Rate by Drug (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Anti-VEGF Agents
Table 3. Key Players of Corticosteroids / Steroid Implants
Table 4. Key Players of Thrombolytic / Enzymatic Agents
Table 5. Key Players of Others
Table 6. Global Intravitreal Injections Market Size Growth Rate by Formulation Type (US$ Million): 2020 VS 2024 VS 2031
Table 7. Key Players of Solution for Intravitreal Injection
Table 8. Key Players of Suspension for Intravitreal Injection
Table 9. Key Players of Others
Table 10. Global Intravitreal Injections Market Size Growth Rate by Duration of Action (US$ Million): 2020 VS 2024 VS 2031
Table 11. Key Players of Short-acting (4–6 weeks)
Table 12. Key Players of Medium-acting (8–12 weeks)
Table 13. Key Players of Long-acting (> 6 months)
Table 14. Global Intravitreal Injections Market Size Growth by Disease (US$ Million): 2020 VS 2024 VS 2031
Table 15. Global Intravitreal Injections Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 16. Global Intravitreal Injections Market Size by Region (2020-2025) & (US$ Million)
Table 17. Global Intravitreal Injections Market Share by Region (2020-2025)
Table 18. Global Intravitreal Injections Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 19. Global Intravitreal Injections Market Share by Region (2026-2031)
Table 20. Intravitreal Injections Market Trends
Table 21. Intravitreal Injections Market Drivers
Table 22. Intravitreal Injections Market Challenges
Table 23. Intravitreal Injections Market Restraints
Table 24. Global Intravitreal Injections Revenue by Players (2020-2025) & (US$ Million)
Table 25. Global Intravitreal Injections Market Share by Players (2020-2025)
Table 26. Global Top Intravitreal Injections Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intravitreal Injections as of 2024)
Table 27. Ranking of Global Top Intravitreal Injections Companies by Revenue (US$ Million) in 2024
Table 28. Global 5 Largest Players Market Share by Intravitreal Injections Revenue (CR5 and HHI) & (2020-2025)
Table 29. Global Key Players of Intravitreal Injections, Headquarters and Area Served
Table 30. Global Key Players of Intravitreal Injections, Product and Application
Table 31. Global Key Players of Intravitreal Injections, Date of Enter into This Industry
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Intravitreal Injections Market Size by Drug (2020-2025) & (US$ Million)
Table 34. Global Intravitreal Injections Revenue Market Share by Drug (2020-2025)
Table 35. Global Intravitreal Injections Forecasted Market Size by Drug (2026-2031) & (US$ Million)
Table 36. Global Intravitreal Injections Revenue Market Share by Drug (2026-2031)
Table 37. Global Intravitreal Injections Market Size by Disease (2020-2025) & (US$ Million)
Table 38. Global Intravitreal Injections Revenue Market Share by Disease (2020-2025)
Table 39. Global Intravitreal Injections Forecasted Market Size by Disease (2026-2031) & (US$ Million)
Table 40. Global Intravitreal Injections Revenue Market Share by Disease (2026-2031)
Table 41. North America Intravitreal Injections Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. North America Intravitreal Injections Market Size by Country (2020-2025) & (US$ Million)
Table 43. North America Intravitreal Injections Market Size by Country (2026-2031) & (US$ Million)
Table 44. Europe Intravitreal Injections Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Europe Intravitreal Injections Market Size by Country (2020-2025) & (US$ Million)
Table 46. Europe Intravitreal Injections Market Size by Country (2026-2031) & (US$ Million)
Table 47. Asia-Pacific Intravitreal Injections Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 48. Asia-Pacific Intravitreal Injections Market Size by Region (2020-2025) & (US$ Million)
Table 49. Asia-Pacific Intravitreal Injections Market Size by Region (2026-2031) & (US$ Million)
Table 50. Latin America Intravitreal Injections Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 51. Latin America Intravitreal Injections Market Size by Country (2020-2025) & (US$ Million)
Table 52. Latin America Intravitreal Injections Market Size by Country (2026-2031) & (US$ Million)
Table 53. Middle East & Africa Intravitreal Injections Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 54. Middle East & Africa Intravitreal Injections Market Size by Country (2020-2025) & (US$ Million)
Table 55. Middle East & Africa Intravitreal Injections Market Size by Country (2026-2031) & (US$ Million)
Table 56. Regeneron Pharmaceuticals Company Details
Table 57. Regeneron Pharmaceuticals Business Overview
Table 58. Regeneron Pharmaceuticals Intravitreal Injections Product
Table 59. Regeneron Pharmaceuticals Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 60. Regeneron Pharmaceuticals Recent Development
Table 61. Bausch & Lomb Company Details
Table 62. Bausch & Lomb Business Overview
Table 63. Bausch & Lomb Intravitreal Injections Product
Table 64. Bausch & Lomb Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 65. Bausch & Lomb Recent Development
Table 66. Novartis Company Details
Table 67. Novartis Business Overview
Table 68. Novartis Intravitreal Injections Product
Table 69. Novartis Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. AbbVie (Allergan) Company Details
Table 72. AbbVie (Allergan) Business Overview
Table 73. AbbVie (Allergan) Intravitreal Injections Product
Table 74. AbbVie (Allergan) Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 75. AbbVie (Allergan) Recent Development
Table 76. Alimera Sciences Company Details
Table 77. Alimera Sciences Business Overview
Table 78. Alimera Sciences Intravitreal Injections Product
Table 79. Alimera Sciences Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 80. Alimera Sciences Recent Development
Table 81. Roche Company Details
Table 82. Roche Business Overview
Table 83. Roche Intravitreal Injections Product
Table 84. Roche Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 85. Roche Recent Development
Table 86. Bristol-Myers Squibb Company Details
Table 87. Bristol-Myers Squibb Business Overview
Table 88. Bristol-Myers Squibb Intravitreal Injections Product
Table 89. Bristol-Myers Squibb Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 90. Bristol-Myers Squibb Recent Development
Table 91. Bayer Company Details
Table 92. Bayer Business Overview
Table 93. Bayer Intravitreal Injections Product
Table 94. Bayer Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 95. Bayer Recent Development
Table 96. Bausch + Lomb Company Details
Table 97. Bausch + Lomb Business Overview
Table 98. Bausch + Lomb Intravitreal Injections Product
Table 99. Bausch + Lomb Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 100. Bausch + Lomb Recent Development
Table 101. EyePoint Pharmaceuticals Company Details
Table 102. EyePoint Pharmaceuticals Business Overview
Table 103. EyePoint Pharmaceuticals Intravitreal Injections Product
Table 104. EyePoint Pharmaceuticals Revenue in Intravitreal Injections Business (2020-2025) & (US$ Million)
Table 105. EyePoint Pharmaceuticals Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
Table 109. Authors List of This Report
List of Figures
Figure 1. Intravitreal Injections Picture
Figure 2. Global Intravitreal Injections Market Size Comparison by Drug (2020-2031) & (US$ Million)
Figure 3. Global Intravitreal Injections Market Share by Drug: 2024 VS 2031
Figure 4. Anti-VEGF Agents Features
Figure 5. Corticosteroids / Steroid Implants Features
Figure 6. Thrombolytic / Enzymatic Agents Features
Figure 7. Others Features
Figure 8. Global Intravitreal Injections Market Size Comparison by Formulation Type (2020-2031) & (US$ Million)
Figure 9. Solution for Intravitreal Injection Features
Figure 10. Suspension for Intravitreal Injection Features
Figure 11. Others Features
Figure 12. Global Intravitreal Injections Market Size Comparison by Duration of Action (2020-2031) & (US$ Million)
Figure 13. Short-acting (4–6 weeks) Features
Figure 14. Medium-acting (8–12 weeks) Features
Figure 15. Long-acting (> 6 months) Features
Figure 16. Global Intravitreal Injections Market Size by Disease (2020-2031) & (US$ Million)
Figure 17. Global Intravitreal Injections Market Share by Disease: 2024 VS 2031
Figure 18. Macular Degeneration Case Studies
Figure 19. Macular Edema Case Studies
Figure 20. Uveitis Case Studies
Figure 21. Retinal Vein Occlusion Case Studies
Figure 22. Others Case Studies
Figure 23. Intravitreal Injections Report Years Considered
Figure 24. Global Intravitreal Injections Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 25. Global Intravitreal Injections Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 26. Global Intravitreal Injections Market Share by Region: 2024 VS 2031
Figure 27. Global Intravitreal Injections Market Share by Players in 2024
Figure 28. Global Intravitreal Injections Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 29. The Top 10 and 5 Players Market Share by Intravitreal Injections Revenue in 2024
Figure 30. North America Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. North America Intravitreal Injections Market Share by Country (2020-2031)
Figure 32. United States Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Canada Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Europe Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Europe Intravitreal Injections Market Share by Country (2020-2031)
Figure 36. Germany Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. France Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. U.K. Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Italy Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Russia Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Ireland Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Intravitreal Injections Market Share by Region (2020-2031)
Figure 44. China Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Japan Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. South Korea Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Southeast Asia Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. India Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Australia & New Zealand Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Latin America Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Latin America Intravitreal Injections Market Share by Country (2020-2031)
Figure 52. Mexico Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Brazil Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Middle East & Africa Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Middle East & Africa Intravitreal Injections Market Share by Country (2020-2031)
Figure 56. Israel Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Saudi Arabia Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 58. UAE Intravitreal Injections Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 59. Regeneron Pharmaceuticals Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 60. Bausch & Lomb Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 61. Novartis Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 62. AbbVie (Allergan) Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 63. Alimera Sciences Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 64. Roche Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 65. Bristol-Myers Squibb Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 66. Bayer Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 67. Bausch + Lomb Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 68. EyePoint Pharmaceuticals Revenue Growth Rate in Intravitreal Injections Business (2020-2025)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
